Abstract
The regulator of G‐protein signaling 5 (RGS5) belongs to a family of GTPase activators that terminate signaling cascades initiated by extracellular mediators and GPCRs. One RGS5 role is as a pericyte biomarker influencing the switch to angiogenesis during malignant progression. Its other role is to promote apoptosis in hypoxic environments. We set out to clarify the extent to which RGS5 expression regulates tumor progression – whether it plays a pathogenic or protective role. We thus constructed an inducible gene expression system to achieve RGS5 expression in HeyA8‐ MDR ovarian cancer cells. Through this we observed that inducible RGS5 expression significantly reduces in vitro BrdU‐positive HeyA8‐MDR cells. Interestingly, mice bearing RGS5‐ expressing tumors demonstrated an increase in survival compared with controls, which might be attributed to the vast regions of necrosis observed by pathological examination. Additionally, mice bearing RGS5‐expressing tumors were less likely to have ulcerated tumors. Taken together, this data supports the idea that temporal expression and stabilization of RGS5 could be a valuable tactic within the context of a multi‐component approach for modulating tumor progression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.